摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Bis(p-sulfonatophenyl)phenylphosphine dipotassium salt

中文名称
——
中文别名
——
英文名称
Bis(p-sulfonatophenyl)phenylphosphine dipotassium salt
英文别名
dipotassium;4-[phenyl-(4-sulfonatophenyl)phosphanyl]benzenesulfonate
Bis(p-sulfonatophenyl)phenylphosphine dipotassium salt化学式
CAS
——
化学式
C18H13K2O6PS2
mdl
——
分子量
498.6
InChiKey
UNZGQTOBCSKUQP-UHFFFAOYSA-L
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -4.74
  • 重原子数:
    29
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    131
  • 氢给体数:
    0
  • 氢受体数:
    6

文献信息

  • PROCESS FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE THROUGH COUPLING USING TRANSITION METAL CATALYST
    申请人:Komiyama Masato
    公开号:US20110313169A1
    公开(公告)日:2011-12-22
    A process for efficiently producing, through few steps either a xanthine oxidase inhibitor, which is a therapeutic agent for hyperuricemia, or an intermediate therefore. The process is a novel coupling process which comprises subjecting a compound represented by formula (1) to coupling reaction with a compound represented by formula (2) in the presence of a transition metal compound to thereby obtain a compound represented by formula (3).
    一种高效生产黄嘌呤氧化酶抑制剂或其中间体的方法,该抑制剂是治疗高尿酸血症的药物。该方法是一种新型偶联过程,包括将式(1)表示的化合物与式(2)表示的化合物在过渡属化合物存在下进行偶联反应,从而获得式(3)表示的化合物。
  • CYCLOPOLYARYLENE COMPOUND AND METHOD OF MANUFACTURING SAME
    申请人:Itami Kenichiro
    公开号:US20140066661A1
    公开(公告)日:2014-03-06
    A cyclopolyarylene compound represented by Formula (1): wherein k is the same or different, and each represents 0, 1 or 2; m is the same or different, and each represents 1, 2 or 3; and n represents 3, 4, 5 or 6.
    由下式表示的环形多芳烃化合物(1): 其中k相同或不同,每个代表0、1或2;m相同或不同,每个代表1、2或3;n代表3、4、5或6。
  • METHOD FOR PRODUCING PHENYL-SUBSTITUTED HETEROCYCLIC DERIVATIVE BY MEANS OF COUPLING METHOD USING PALLADIUM COMPOUND
    申请人:Komiyama Masato
    公开号:US20130158272A1
    公开(公告)日:2013-06-20
    The present invention provides a method for producing a xanthine oxidase inhibitor, which is a therapeutic agent for hyperuricemia, or intermediates of the same, said method being efficient and using a short process. The present invention is a novel coupling method for obtaining a compound represented by formula (3) by bringing about a coupling reaction between a compound represented by formula (1) and a compound represented by formula (2), in the presence of a palladium compound, a ligand capable of coordinating to the palladium compound, a base, a C 1 -C 40 carboxylic acid, and at least one kind of additive.
    本发明提供了一种生产黄嘌呤氧化酶抑制剂的方法,该抑制剂是治疗高尿酸血症的药物,或者其中间体,该方法高效且使用流程简短。本发明是一种新型耦合方法,通过在化合物、能够配位到化合物的配体、碱、C1-C40羧酸和至少一种添加剂的存在下,在式(1)所代表的化合物和式(2)所代表的化合物之间引发耦合反应,从而获得式(3)所代表的化合物。
  • CYCLIC COMPOUND CONTAINING FUNCTIONAL GROUP OR CONTAINING NO FUNCTIONAL GROUP, AND METHOD FOR PRODUCING SAME
    申请人:National University Corporation Nagoya University
    公开号:US20150126779A1
    公开(公告)日:2015-05-07
    This invention selectively synthesizes a cycloparaphenylene compound having 10, 11, or 13 benzene rings. The invention also synthesizes a cycloparaphenylene compound in which a functional group is introduced into a desired portion. By reacting specific raw materials using a specific reaction, a cyclic compound having 10, 11, or 13 bivalent aromatic hydrocarbon groups, bivalent heterocyclic groups, or derivative groups thereof can be selectively obtained as a pure substance. Further, by a method comprising the step of reacting a specific organic compound containing no functional group with a specific organic compound containing a functional group, it is possible to obtain a cyclic compound containing a functional group in which one or more bivalent aromatic hydrocarbon groups, bivalent heterocyclic groups, or derivative groups thereof of a compound having 10 or more bivalent aromatic hydrocarbon groups, bivalent heterocyclic groups, or derivative groups thereof is substituted with a substituted 1,4-phenylene group.
    这项发明选择性地合成了具有10、11或13个苯环的环对苯基化合物。该发明还合成了将功能基引入所需部位的环对苯基化合物。通过使用特定的反应剂对特定的原料进行反应,可以选择性地获得纯物质的具有10、11或13个双价芳香烃基、双价杂环基或其衍生物基团的环状化合物。此外,通过将不含功能基的特定有机化合物与含有功能基的特定有机化合物反应的步骤,可以获得含有功能基的环状化合物,其中10个或更多个双价芳香烃基、双价杂环基或其衍生物基团的化合物中的一个或多个被取代的1,4-苯基烷基所代替。
  • 1,3,5-TRIAZINE DERIVATIVE, PRODUCTION METHOD THEREOF AND ORGANIC ELECTROLUMINESCENCE DEVICE COMPRISING THIS AS A COMPOSING COMPONENT
    申请人:Yamakawa Tetsu
    公开号:US20090281311A1
    公开(公告)日:2009-11-12
    Since the conventional electron transporters have low thermal stability, the organic electroluminescent devices using them are not sufficient in terms of the compatibility of their luminance and luminous efficiency with device lifetime. A 1,3,5-triazine derivative of formula (1) is obtained by a metal catalyst-aided coupling reaction of a compound of formula (2) with a compound of formula (3), and this is used as a composing component of an organic electroluminescent device. [In the formulae, Ar 1 and Ar 2 represent phenyl group or the like, R 1 and R 2 represent hydrogen atom or the like, R 3 represents methyl or the like, m is an integer of 0 to 2, X represents 2,4-pyridylene or the like, p is 1 or 2, a and b are 1 or 2, a+b is 3, q is 0 or an integer of p or less, M represents —MgR 4 group or the like, R 4 represents chlorine atom or the like, r is p-q, and Y represents a leaving group.]
    由于传统的电子传输体具有低热稳定性,使用它们的有机电致发光器件在亮度和发光效率与器件寿命的兼容性方面不足。通过化合物(2)和化合物(3)的属催化偶联反应获得式(1)的1,3,5-三嗪生物,并将其用作有机电致发光器件的组成部分。[在公式中,Ar1和Ar2代表苯基或类似基团,R1和R2代表氢原子或类似原子团,R3代表甲基或类似基团,m为0至2的整数,X代表2,4-吡啶基或类似基团,p为1或2,a和b为1或2,a+b为3,q为0或小于等于p的整数,M代表-MgR4基团或类似基团,R4代表原子或类似原子团,r为p-q,Y代表离去基团。]
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫